| Year |
Citation |
Score |
| 2024 |
Wang Y, Scurll J, Rascón IA, Cui C, Ni Y, Shi AM, Gangadharannambiar P, Wang Y, Akamatsu S, Beltran H, Cox M, Crea F, Daugaard M, Dong X, Haffner M, ... ... Zoubeidi A, et al. The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions. Epigenomics. 1-4. PMID 39225130 DOI: 10.1080/17501911.2024.2391729 |
0.547 |
|
| 2024 |
Nouruzi S, Johnson F, Kumar S, Sivak O, Tabrizian N, Koistinaho M, Muona A, Zoubeidi A. Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308. Oncology Reports. 52. PMID 39129317 DOI: 10.3892/or.2024.8791 |
0.589 |
|
| 2024 |
Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu EC, Shen M, Shaw Toland AM, Bermudez A, Hartono AB, Massey CF, Lee CS, Zheng L, Baron M, Denning CJ, Aslan M, ... ... Zoubeidi A, et al. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. Cell Reports. Medicine. 101381. PMID 38244540 DOI: 10.1016/j.xcrm.2023.101381 |
0.341 |
|
| 2024 |
Kaarijärvi R, Kaljunen H, Nappi L, Fazli L, Kung SHY, Hartikainen JM, Paakinaho V, Capra J, Rilla K, Malinen M, Mäkinen PI, Ylä-Herttuala S, Zoubeidi A, Wang Y, Gleave ME, et al. DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2. Communications Biology. 7: 108. PMID 38238517 DOI: 10.1038/s42003-023-05741-x |
0.626 |
|
| 2023 |
Crowell PD, Giafaglione JM, Jones AE, Nunley NM, Hashimoto T, Delcourt AML, Petcherski A, Agrawal R, Bernard MJ, Diaz JA, Heering KY, Huang RR, Low JY, Matulionis N, Navone NM, ... ... Zoubeidi A, et al. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Reports. 42: 113221. PMID 37815914 DOI: 10.1016/j.celrep.2023.113221 |
0.564 |
|
| 2023 |
Rawat C, Ben-Salem S, Singh N, Chauhan G, Rabljenovic A, Vaghela V, Venkadakrishnan VB, Macdonald JD, Dahiya UR, Ghanem Y, Bachour S, Su Y, DePriest AD, Lee S, Muldong M, ... ... Zoubeidi A, et al. Prostate cancer progression relies on the mitotic kinase citron kinase. Cancer Research. PMID 37801613 DOI: 10.1158/0008-5472.CAN-23-0883 |
0.603 |
|
| 2023 |
Tabrizian N, Nouruzi S, Cui CJ, Kobelev M, Namekawa T, Lodhia I, Talal A, Sivak O, Ganguli D, Zoubeidi A. ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer. Cell Reports. 42: 112937. PMID 37552603 DOI: 10.1016/j.celrep.2023.112937 |
0.488 |
|
| 2023 |
Habault J, Schneider JA, Ha S, Ruoff R, Doro Pereira LD, Puccini J, Ranieri M, Ayasun R, Deng J, Kasper AC, Bar-Sagi D, Wong KK, Zoubeidi A, Claessens F, Wise DR, et al. A multivalent peptoid conjugate modulates androgen receptor transcriptional activity to inhibit therapy-resistant prostate cancer. Molecular Cancer Therapeutics. PMID 37486978 DOI: 10.1158/1535-7163.MCT-23-0196 |
0.618 |
|
| 2023 |
Nouruzi S, Tabrizian N, Zoubeidi A. Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer. Endocrinology. 164. PMID 36718085 DOI: 10.1210/endocr/bqad023 |
0.616 |
|
| 2022 |
Lelong EIJ, Khelifi G, Adjibade P, Joncas FH, Grenier St-Sauveur V, Paquette V, Gris T, Zoubeidi A, Audet-Walsh E, Lambert JP, Toren P, Mazroui R, Hussein SMI. Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation. Nar Cancer. 4: zcac034. PMID 36348939 DOI: 10.1093/narcan/zcac034 |
0.403 |
|
| 2022 |
Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, ... ... Zoubeidi A, et al. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Research. OF1-OF15. PMID 36251389 DOI: 10.1158/0008-5472.CAN-22-1123 |
0.556 |
|
| 2022 |
Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, Alkemade M, Bekers EM, Severson TM, Sanders J, Huang CF, Morova T, Altintas UB, Hoekman L, Kim Y, ... ... Zoubeidi A, et al. Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence. Cancer Discovery. PMID 35754340 DOI: 10.1158/2159-8290.CD-21-0576 |
0.604 |
|
| 2022 |
Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T, Thaper D, Baca SC, Freedman ML, Aguda A, Davies A, Zoubeidi A. ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nature Communications. 13: 2282. PMID 35477723 DOI: 10.1038/s41467-022-29963-5 |
0.411 |
|
| 2021 |
Monga J, Adrianto I, Rogers C, Gadgeel S, Chitale D, Alumkal JJ, Beltran H, Zoubeidi A, Ghosh J. Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. The Journal of Biological Chemistry. 101556. PMID 34973338 DOI: 10.1016/j.jbc.2021.101556 |
0.646 |
|
| 2021 |
Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, ... ... Zoubeidi A, et al. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications. 12: 7349. PMID 34934057 DOI: 10.1038/s41467-021-26901-9 |
0.454 |
|
| 2021 |
Che M, Chaturvedi A, Munro SA, Pitzen SP, Ling A, Zhang W, Mentzer J, Ku SY, Puca L, Zhu Y, Bergman AM, Severson TM, Forster C, Liu Y, Hildebrand J, ... ... Zoubeidi A, et al. Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications. 12: 6377. PMID 34737261 DOI: 10.1038/s41467-021-26612-1 |
0.554 |
|
| 2021 |
Sooreshjani MA, Kamra M, Zoubeidi A, Shah K. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models. Journal of Biomedical Science. 28: 68. PMID 34625072 DOI: 10.1186/s12929-021-00765-z |
0.609 |
|
| 2021 |
Kuznik NC, Solozobova V, Jung N, Gräßle S, Lei Q, Lewandowski EM, Munuganti R, Zoubeidi A, Chen Y, Bräse S, Cato ACB. Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer. Acs Chemical Biology. PMID 34506104 DOI: 10.1021/acschembio.1c00390 |
0.563 |
|
| 2021 |
Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoğlanoğlu F, Omur ME, Kim S, Kobelev M, Kumar S, Sivak O, Bostock C, Bishop J, Hoogstraat M, ... ... Zoubeidi A, et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature Cell Biology. PMID 34489572 DOI: 10.1038/s41556-021-00743-5 |
0.538 |
|
| 2021 |
Ghosh PM, Zoubeidi A. Celebrating the 80th anniversary of hormone ablation for prostate cancer. Endocrine-Related Cancer. PMID 34187942 DOI: 10.1530/ERC-21-0192 |
0.61 |
|
| 2021 |
Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, ... ... Zoubeidi A, et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature Communications. 12: 1979. PMID 33785741 DOI: 10.1038/s41467-021-22139-7 |
0.608 |
|
| 2021 |
Peter MR, Bilenky M, Davies A, Isserlin R, Bader GD, Fleshner NE, Hirst M, Zoubeidi A, Bapat B. Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer. Scientific Reports. 11: 6630. PMID 33758253 DOI: 10.1038/s41598-021-85812-3 |
0.476 |
|
| 2021 |
Ahmed M, Soares F, Xia JH, Yang Y, Li J, Guo H, Su P, Tian Y, Lee HJ, Wang M, Akhtar N, Houlahan KE, Bosch A, Zhou S, Mazrooei P, ... ... Zoubeidi A, et al. CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. Nature Communications. 12: 1781. PMID 33741908 DOI: 10.1038/s41467-021-21867-0 |
0.362 |
|
| 2021 |
Liang Y, Jeganathan S, Marastoni S, Sharp A, Figueiredo I, Marcellus R, Mawson A, Shalev Z, Pesic A, Sweet J, Guo H, Uehling D, Gurel B, Neeb AJ, He HH, ... ... Zoubeidi A, et al. Emergence of Enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33542074 DOI: 10.1158/1078-0432.CCR-20-3260 |
0.537 |
|
| 2021 |
Fernandes RC, Toubia J, Townley S, Hanson AR, Dredge BK, Pillman KA, Bert AG, Winter JM, Iggo R, Das R, Obinata D, Sandhu S, Risbridger GP, Taylor RA, ... ... Zoubeidi A, et al. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Reports. 34: 108585. PMID 33406413 DOI: 10.1016/j.celrep.2020.108585 |
0.538 |
|
| 2020 |
Lounis MA, Péant B, Leclerc-Desaulniers K, Ganguli D, Daneault C, Ruiz M, Zoubeidi A, Mes-Masson AM, Saad F. Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer. Cancers. 12. PMID 33187317 DOI: 10.3390/cancers12113339 |
0.613 |
|
| 2020 |
Samiea A, Yoon JSJ, Ong CJ, Zoubeidi A, Chamberlain TC, Mui AL. Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells. Prostate Cancer. 2020: 5305306. PMID 32802517 DOI: 10.1155/2020/5305306 |
0.646 |
|
| 2020 |
Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, ... ... Zoubeidi A, et al. The DNA methylation landscape of advanced prostate cancer. Nature Genetics. PMID 32661416 DOI: 10.1038/S41588-020-0648-8 |
0.501 |
|
| 2020 |
Tiwari R, Manzar N, Bhatia V, Yadav A, Nengroo MA, Datta D, Carskadon S, Gupta N, Sigouros M, Khani F, Poutanen M, Zoubeidi A, Beltran H, Palanisamy N, Ateeq B. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. Nature Communications. 11: 384. PMID 31959826 DOI: 10.1038/S41467-019-14184-0 |
0.654 |
|
| 2020 |
Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, Ghoochani A, Zhang CA, Chen YS, Zlitni A, Kumar S, Nolley R, Habte F, Shen M, Koul K, ... ... Zoubeidi A, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proceedings of the National Academy of Sciences of the United States of America. PMID 31932422 DOI: 10.1073/Pnas.1905384117 |
0.698 |
|
| 2020 |
Munuganti R, Thaper D, Aguda A, Kim S, Sivak O, Zoubeidi A. Abstract 14: Computer-aided discovery of small-molecule inhibitors targeting neural transcription factor BRN2 in neuroendocrine prostate tumors Clinical Cancer Research. 26: 14-14. DOI: 10.1158/1557-3265.Advprecmed20-14 |
0.624 |
|
| 2020 |
Thaper D, Munuganti R, Aguda A, Kim S, Ku S, Kumar S, Vahid S, Nouruzi S, Sivak O, Ganguli D, Morrissey C, Corey E, Beltran H, Zoubeidi A. Abstract 3083: Selective inhibition of transcription factor BRN2 as a treatment strategy for Small Cell Prostate Cancer Cancer Research. 80: 3083-3083. DOI: 10.1158/1538-7445.Am2020-3083 |
0.636 |
|
| 2019 |
Thaper D, Vahid S, Zoubeidi A. Neural Transcription Factors in Disease Progression. Advances in Experimental Medicine and Biology. 1210: 437-462. PMID 31900920 DOI: 10.1007/978-3-030-32656-2_19 |
0.679 |
|
| 2019 |
Nappi L, Aguda AH, Nakouzi NA, Lelj-Garolla B, Beraldi E, Lallous N, Thi M, Moore S, Fazli L, Battsogt D, Stoffeliene S, Ban F, Nguyen NT, Saxena N, Dueva E, ... ... Zoubeidi A, et al. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. The Journal of Clinical Investigation. PMID 31845908 DOI: 10.1172/Jci130819 |
0.487 |
|
| 2019 |
Davies AH, Zoubeidi A, Selth LA. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. Endocrine-Related Cancer. PMID 31804971 DOI: 10.1530/Erc-19-0420 |
0.602 |
|
| 2019 |
Ramnarine VR, Kobelev M, Gibb EA, Nouri M, Lin D, Wang Y, Buttyan R, Davicioni E, Zoubeidi A, Collins CC. The evolution of long noncoding RNA acceptance in prostate cancer initiation and progression, and its clinical utility in disease management. European Urology. PMID 31445843 DOI: 10.1016/J.Eururo.2019.07.040 |
0.538 |
|
| 2019 |
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, ... ... Zoubeidi A, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31363002 DOI: 10.1158/1078-0432.Ccr-19-1423 |
0.678 |
|
| 2019 |
Kim S, Thaper D, Bidnur S, Toren P, Akamatsu S, Bishop JL, Colins C, Vahid S, Zoubeidi A. PEG10 is associated with treatment-induced neuroendocrine prostate cancer. Journal of Molecular Endocrinology. PMID 31013476 DOI: 10.1530/Jme-18-0226 |
0.604 |
|
| 2019 |
Davies A, Conteduca V, Zoubeidi A, Beltran H. Biological Evolution of Castration-resistant Prostate Cancer. European Urology Focus. PMID 30772358 DOI: 10.1016/J.Euf.2019.01.016 |
0.631 |
|
| 2019 |
Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, ... ... Zoubeidi A, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications. 10: 278. PMID 30655535 DOI: 10.1038/S41467-018-08133-6 |
0.623 |
|
| 2019 |
Jain P, Clermont PL, Desmeules F, Zoubeidi A, Neveu B, Pouliot F. Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells. International Journal of Molecular Sciences. 20. PMID 30626088 DOI: 10.3390/Ijms20010216 |
0.608 |
|
| 2019 |
Thaper DL, Munuganti R, Nouruzi S, Kumar S, Kim S, Vahid S, Sivak O, Aguda A, Puca L, Beltran H, Zoubeidi A. First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer. Journal of Clinical Oncology. 37: 260-260. DOI: 10.1200/Jco.2019.37.7_Suppl.260 |
0.59 |
|
| 2019 |
Nappi L, Kesch C, Vahid S, Fazli L, Eigl BJ, Kollmannsberger CK, Gleave M, Zoubeidi A, Wyatt AW, Chi KN. Immunogenomic landscape of neuroendocrine small cell prostate cancer. Journal of Clinical Oncology. 37: 217-217. DOI: 10.1200/Jco.2019.37.7_Suppl.217 |
0.675 |
|
| 2019 |
Thaper D, Munuganti R, Nouruzi S, Kumar S, Kim S, Sivak O, Aguda A, Ganguli D, Vahid S, Puca L, Beltran H, Zoubeidi A. Abstract 1295: First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1295 |
0.579 |
|
| 2019 |
Tiwari R, Manzar N, Bhatia V, Yadav A, Carskadon S, Gupta N, Zoubeidi A, Palanisamy N, Ateeq B. Abstract 5225: Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer Cancer Research. 79: 5225-5225. DOI: 10.1158/1538-7445.Am2019-5225 |
0.689 |
|
| 2019 |
Beltran H, Ku S, Conteduca V, Romanel A, Puca L, Sigouros M, Mosquera JM, Tagawa ST, Sboner A, Elemento O, Goodrich D, Rickman D, Zoubeidi A, Demichelis F. Abstract CN06-01: Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Cn06-01 |
0.642 |
|
| 2019 |
Manzar N, Tiwari R, Bhatia V, Yadav A, Carskadon S, Gupta N, Zoubeidi A, Poutanen M, Beltran H, Palanisamy N, Ateeq B. Abstract C128: Reprogramming transcription factors SOX2 and REST modulates SPINK1 expression in governing cellular plasticity in prostate cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C128 |
0.686 |
|
| 2018 |
Thaper D, Vahid S, Kaur R, Kumar S, Nouruzi S, Bishop JL, Johansson M, Zoubeidi A. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer. Scientific Reports. 8: 17307. PMID 30470788 DOI: 10.1038/S41598-018-35612-Z |
0.671 |
|
| 2018 |
Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, ... ... Zoubeidi A, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 175: 889. PMID 30340047 DOI: 10.1016/J.Cell.2018.10.019 |
0.582 |
|
| 2018 |
Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, ... ... Zoubeidi A, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. PMID 30033370 DOI: 10.1016/J.Cell.2018.06.039 |
0.576 |
|
| 2018 |
Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, Larson NB, McDonnell SK, Patel PS, Liang Y, Yao CQ, ... ... Zoubeidi A, et al. Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. Cell. PMID 30033362 DOI: 10.1016/J.Cell.2018.06.014 |
0.408 |
|
| 2018 |
Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, ... ... Zoubeidi A, et al. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. PMID 29757368 DOI: 10.1093/Gigascience/Giy050 |
0.613 |
|
| 2018 |
Zoubeidi A, Gleave ME. Co-targeting driver pathways in prostate cancer: two birds with one stone. Embo Molecular Medicine. 10. PMID 29572264 DOI: 10.15252/Emmm.201808928 |
0.563 |
|
| 2018 |
Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, et al. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. European Urology. PMID 29544736 DOI: 10.1016/J.Eururo.2018.02.019 |
0.675 |
|
| 2018 |
Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nature Reviews. Urology. PMID 29460922 DOI: 10.1038/Nrurol.2018.22 |
0.692 |
|
| 2018 |
Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, Khazamipour N, Tombe T, Dejima T, Lee KC, Shiota M, Thaper D, Lee WC, Hui DH, Kuruma H, ... ... Zoubeidi A, et al. SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. Embo Molecular Medicine. PMID 29348142 DOI: 10.15252/Emmm.201707689 |
0.612 |
|
| 2018 |
Maxwell PJ, McKechnie M, Duddy O, Armstrong CW, Manley JM, Ong CW, Worthington J, Deryugina E, Quigley JP, Zoubeidi A, Waugh DJJ, LaBonte MJ. Abstract A087: Enzalutamide-induced hypoxia attenuates response and promotes resistance to enzalutamide in preclinical models of prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A087 |
0.648 |
|
| 2018 |
Davies A, Bostock C, Ahmed M, Lin Y, Johnson F, Nip KM, Ketola K, Bishop J, Fazli L, Goodrich D, Hach F, He H, Beltran H, Zoubeidi A. Abstract A033: Identity fraud: Lineage plasticity as a mechanism of antiandrogen resistance and target for therapy Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A033 |
0.604 |
|
| 2018 |
Ci X, Hao J, Dong X, Choi SY, Xue H, Qu S, Fazli L, Crea F, Ong C, Zoubeidi A, He HH, Gleave ME, Collins CC, Lin D, Wang Y. Abstract 773: A heterochromatin gene signature unveils HP1α mediating neuroendocrine prostate cancer development and aggressiveness Cancer Research. 78: 773-773. DOI: 10.1158/1538-7445.Am2018-773 |
0.632 |
|
| 2017 |
Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, ... ... Zoubeidi A, et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology. PMID 29258679 DOI: 10.1016/J.Eururo.2017.11.038 |
0.657 |
|
| 2017 |
Melong N, Steele S, MacDonald M, Holly A, Collins CC, Zoubeidi A, Berman JN, Dellaire G. Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia. Scientific Reports. 7: 14698. PMID 29089623 DOI: 10.1038/S41598-017-14413-W |
0.579 |
|
| 2017 |
Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, ... ... Zoubeidi A, et al. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Research. PMID 28916652 DOI: 10.1158/0008-5472.Can-17-0496 |
0.65 |
|
| 2017 |
Ketola K, Munuganti RS, Davies A, Nip KM, Bishop JL, Zoubeidi A. Targeting Prostate Cancer Subtype 1 by Forkhead box M1 Pathway Inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28899970 DOI: 10.1158/1078-0432.Ccr-17-0901 |
0.603 |
|
| 2017 |
Davies AH, Wang Y, Zoubeidi A. Patient-derived xenografts: A platform for accelerating translational research in prostate cancer. Molecular and Cellular Endocrinology. PMID 28315377 DOI: 10.1016/J.Mce.2017.03.013 |
0.584 |
|
| 2017 |
Thaper D, Vahid S, Nip KM, Moskalev I, Shan X, Frees S, Roberts ME, Ketola K, Harder KW, Gregory-Evans C, Bishop JL, Zoubeidi A. Targeting Lyn regulates Snail family shuttling and inhibits metastasis. Oncogene. PMID 28288135 DOI: 10.1038/Onc.2017.5 |
0.381 |
|
| 2017 |
Davies A, Ahmed M, Bostock C, Gleave A, Ketola K, Johnson F, Bishop J, Fazli L, Huang H, He H, Zoubeidi A. Abstract 5025: EZH2 reprogramming confers intrinsic stem cell properties and developmental plasticity driving neuroendocrine prostate cancer Cancer Research. 77: 5025-5025. DOI: 10.1158/1538-7445.Am2017-5025 |
0.587 |
|
| 2017 |
Bishop JL, Thaper D, Vahid S, Munuganti RS, Ahn P, Davies A, Ketola K, Nip KM, Lin D, Wang Y, Beltran H, Zoubeidi A. Abstract 3189: Neuronal transcription factor BRN2 is an androgen suppressed driver of neuroendocrine differentiation in prostate cancer Cancer Research. 77: 3189-3189. DOI: 10.1158/1538-7445.Am2017-3189 |
0.661 |
|
| 2016 |
Wilson MR, Zoubeidi A. Clusterin as a therapeutic target. Expert Opinion On Therapeutic Targets. 1-13. PMID 27978767 DOI: 10.1080/14728222.2017.1267142 |
0.53 |
|
| 2016 |
Vahid S, Thaper D, Zoubeidi A. Chaperoning the cancer: The proteostatic functions of the heat shock proteins in cancer. Recent Patents On Anti-Cancer Drug Discovery. PMID 27809750 DOI: 10.2174/1574892811666161102125252 |
0.458 |
|
| 2016 |
Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, ... ... Zoubeidi A, et al. The Master Neural Transcription Factor BRN2 is an Androgen Receptor Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery. PMID 27784708 DOI: 10.1158/2159-8290.Cd-15-1263 |
0.666 |
|
| 2016 |
Luk IS, Shrestha R, Xue H, Wang Y, Zhang F, Lin D, Haegert A, Wu R, Dong X, Collins CC, Zoubeidi A, Gleave ME, Gout PW, Wang Y. BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27663589 DOI: 10.1158/1078-0432.Ccr-16-0718 |
0.549 |
|
| 2016 |
Vahid S, Thaper D, Gibson KF, Bishop JL, Zoubeidi A. Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer. Scientific Reports. 6: 31842. PMID 27555231 DOI: 10.1038/Srep31842 |
0.52 |
|
| 2016 |
Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME. Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55]. European Urology. 70: e27-e28. PMID 27302299 DOI: 10.1016/J.Eururo.2016.03.014 |
0.505 |
|
| 2016 |
Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, Stylianou N, Sweeney K, Soekmadji C, Jovanovic L, Nelson CC, Zoubeidi A, Butler LM, Goodall GJ, Hollier BG, et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. PMID 27270433 DOI: 10.1038/Onc.2016.185 |
0.444 |
|
| 2016 |
Toren P, Kim S, Johnson F, Zoubeidi A. Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. Plos One. 11: e0152861. PMID 27046225 DOI: 10.1200/Jco.2016.34.2_Suppl.192 |
0.68 |
|
| 2016 |
Davies AH, Zoubeidi A. The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells. Stem Cells International. 2016: 4829602. PMID 26880966 DOI: 10.1155/2016/4829602 |
0.411 |
|
| 2016 |
Toren P, Zoubeidi A, Allman J. Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer. Journal of Clinical Oncology. 34: 234-234. DOI: 10.1200/Jco.2016.34.2_Suppl.234 |
0.639 |
|
| 2016 |
Vahid S, Thaper D, Davies A, Rensburg MJV, Gibson K, Ketola K, Johansson M, Bishop JL, Zoubeidi A. Abstract 3342: Galiellalactone derivative targets stem cell population in ENZ-resistant prostate cancer through inhibition of STAT3 Cancer Research. 76: 3342-3342. DOI: 10.1158/1538-7445.Am2016-3342 |
0.603 |
|
| 2016 |
Thaper D, Vahid S, Nip KM, Moskalev I, Frees S, Roberts ME, Ketola K, Harder KW, Bishop JL, Zoubeidi A. Abstract 1682: Lyn drives cancer metastasis via post-translational regulation of SNAI proteins Cancer Research. 76: 1682-1682. DOI: 10.1158/1538-7445.Am2016-1682 |
0.53 |
|
| 2016 |
Akamatsu S, Wyatt A, Lin D, Lysakowski S, Zhang F, Kawai Y, Fazli L, Ogawa O, Lotan T, Rubin M, Beltran H, Zoubeidi A, Wang Y, Gleave M, Collins C. 138 Exploring a novel therapeutic target for neuroendocrine prostate cancer using a xenograft model of trans-differentiation European Urology Supplements. 15: e138. DOI: 10.1016/S1569-9056(16)60140-9 |
0.629 |
|
| 2016 |
Toren P, Kim S, Zoubeidi A. Mp62-06 Combined Akt And Mek Pathway Blockade In Pre-Clinical Models Of Enzalutamide-Resistant Prostate Cancer The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.914 |
0.643 |
|
| 2016 |
Njar V, Zoubeidi A, Corey E, Mostaghel E, Kwegyir-Afful A, Ramalingam S, Jacoby D. PD32-07 GALETERONE SHOWS ANTI-TUMOR ACTIVITY IN MULTIPLE PRE-CLINICAL MODELS THAT EXPRESS ANDROGEN RECEPTOR SPLICE VARIANTS, SUPPORTING CORRELATIVE PATIENT DATA SEEN IN ARMOR2 Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.683 |
0.326 |
|
| 2016 |
Toren P, Allman J, Kim S, Zoubeidi A. PD32-01 PRE-CLINICAL RATIONALE FOR COMBINATION PI3K AND BRD4 INHIBITION IN ADVANCED PROSTATE CANCER Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.677 |
0.555 |
|
| 2016 |
Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME. Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55] European Urology. DOI: 10.1016/j.eururo.2016.03.014 |
0.411 |
|
| 2015 |
Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR. Erratum: Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget. 6: 34038. PMID 26513314 DOI: 10.18632/oncotarget.6187 |
0.567 |
|
| 2015 |
Li J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, Ratliff TL, Konieczny SF, Liu X. Co-targeting Polo-like kinase 1(Plk1) and the Wnt/β-catenin signaling pathway in castration-resistant prostate cancer. Molecular and Cellular Biology. PMID 26438599 DOI: 10.1128/Mcb.00825-15 |
0.55 |
|
| 2015 |
Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Kawai Y, Xue H, ... ... Zoubeidi A, et al. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Reports. PMID 26235627 DOI: 10.1016/J.Celrep.2015.07.012 |
0.667 |
|
| 2015 |
Xia Y, Wang M, Beraldi E, Cong M, Zoubeidi A, Gleave M, Peng L. A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor. Anti-Cancer Agents in Medicinal Chemistry. PMID 26081200 DOI: 10.2174/1871520615666150617110943 |
0.642 |
|
| 2015 |
Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR. Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget. 6: 14318-28. PMID 26015409 DOI: 10.18632/Oncotarget.3960 |
0.615 |
|
| 2015 |
Bishop JL, Davies A, Ketola K, Zoubeidi A. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocrine-Related Cancer. 22: R165-82. PMID 25934687 DOI: 10.1530/Erc-15-0137 |
0.659 |
|
| 2015 |
Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget. 6: 9086-98. PMID 25871401 DOI: 10.18632/Oncotarget.3602 |
0.598 |
|
| 2015 |
Fokidis HB, Yieng Chin M, Ho VW, Adomat HH, Soma KK, Fazli L, Nip KM, Cox M, Krystal G, Zoubeidi A, Tomlinson Guns ES. A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice. The Journal of Steroid Biochemistry and Molecular Biology. 150: 35-45. PMID 25797030 DOI: 10.1016/J.Jsbmb.2015.03.006 |
0.364 |
|
| 2015 |
Lelj-Garolla B, Kumano M, Beraldi E, Nappi L, Rocchi P, Ionescu DN, Fazli L, Zoubeidi A, Gleave ME. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Molecular Cancer Therapeutics. 14: 1107-16. PMID 25740245 DOI: 10.1158/1535-7163.Mct-14-0866 |
0.426 |
|
| 2015 |
Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Nakouzi NA, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, et al. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1675-87. PMID 25634993 DOI: 10.1158/1078-0432.Ccr-14-1108 |
0.654 |
|
| 2015 |
Azad AA, Zoubeidi A, Gleave ME, Chi KN. Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nature Reviews. Urology. 12: 26-36. PMID 25512207 DOI: 10.1038/Nrurol.2014.320 |
0.591 |
|
| 2015 |
Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 6: 234-42. PMID 25428917 DOI: 10.18632/Oncotarget.2703 |
0.38 |
|
| 2015 |
Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, Zoubeidi A, Moore W, Gleave ME. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Molecular Cancer Therapeutics. 14: 59-69. PMID 25351916 DOI: 10.1158/1535-7163.Mct-14-0521 |
0.587 |
|
| 2015 |
Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. European Urology. 67: 986-90. PMID 25151012 DOI: 10.1016/J.Eururo.2014.08.006 |
0.648 |
|
| 2015 |
Cordonnier T, Bishop JL, Shiota M, Nip KM, Thaper D, Vahid S, Heroux D, Gleave M, Zoubeidi A. Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer. International Journal of Cancer. Journal International Du Cancer. 136: E496-507. PMID 25130271 DOI: 10.1002/Ijc.29122 |
0.542 |
|
| 2015 |
Bishop JL, Thaper DL, Vaheid S, Johansson MH, Zoubeidi A. Reduction in PD-L1 expression by STAT3 inhibition with GPA500 in enzalutamide-resistant prosate cancer. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16075 |
0.585 |
|
| 2015 |
Crea F, Parolia A, Xue H, Frumento P, Wang Y, Haegert A, Chi KN, Zoubeidi A, Collins C, Wang Y. Identification and functional characterization of a long non-coding RNA driving hormone-independent prostate cancer progression. Journal of Clinical Oncology. 33: 11087-11087. DOI: 10.1200/Jco.2015.33.15_Suppl.11087 |
0.529 |
|
| 2015 |
Jeganathan S, Zoubeidi A, Gleave M, Wouters BG, Joshua AM. Abstract 732: Using functional and chemical genomics to identify mechanisms of Enzalutamide resistance in prostate cancer Cancer Research. 75: 732-732. DOI: 10.1158/1538-7445.Am2015-732 |
0.597 |
|
| 2015 |
Thaper D, Vahid S, Bishop JL, Johansson M, Zoubeidi A. Abstract 728: New derivative of galiellalactone inhibits the STAT3 activity and suppresses ENZ-resistant Prostate Cancerin vitro Cancer Research. 75: 728-728. DOI: 10.1158/1538-7445.Am2015-728 |
0.643 |
|
| 2015 |
Vahid S, Thaper D, Zoubeidi A. Abstract 4956: Hsp27 negatively affects Hippo tumor suppressor pathway to regulate cell survival in cancer Cancer Research. 75: 4956-4956. DOI: 10.1158/1538-7445.Am2015-4956 |
0.609 |
|
| 2015 |
Thaper D, Vahid S, Nip KM, Ketola K, Bishop J, Zoubeidi A. Abstract 4106: Lyn kinase promotes metastasis through EMT in cancers Cancer Research. 75: 4106-4106. DOI: 10.1158/1538-7445.Am2015-4106 |
0.528 |
|
| 2015 |
Jacoby DB, Zoubeidi A, Corey EB, Mostaghel E, Kwegyir-Afful AK, Ramalingam S, Njar V. Abstract B173: Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2 Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B173 |
0.622 |
|
| 2015 |
Takeuchi A, Shiota M, Naito S, Cox M, Gleave M, Zoubeidi A. Mp37-12 Insulin-Like Growth Factor-I Induces Clu Expression Through Twist1 To Promote Prostate Cancer Growth The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1275 |
0.57 |
|
| 2014 |
Zhang F, Kumano M, Beraldi E, Fazli L, Du C, Moore S, Sorensen P, Zoubeidi A, Gleave ME. Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. Nature Communications. 5: 5775. PMID 25503391 DOI: 10.1038/Ncomms6775 |
0.335 |
|
| 2014 |
Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, Ban F, Hsing M, Adomat H, Lallous N, Andre C, Jonadass JP, Zoubeidi A, Young RN, Guns ET, et al. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Chemistry & Biology. 21: 1476-85. PMID 25459660 DOI: 10.1016/J.Chembiol.2014.09.012 |
0.629 |
|
| 2014 |
Pham S, Deb S, Ming DS, Adomat H, Hosseini-Beheshti E, Zoubeidi A, Gleave M, Guns ES. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro. The Journal of Steroid Biochemistry and Molecular Biology. 144: 436-44. PMID 25201454 DOI: 10.1016/J.Jsbmb.2014.09.004 |
0.601 |
|
| 2014 |
Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymann D, Rédini F. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget. 5: 7805-19. PMID 25138053 DOI: 10.18632/Oncotarget.2308 |
0.438 |
|
| 2014 |
Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A. Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer. Oncogenesis. 3: e115. PMID 25133482 DOI: 10.1038/oncsis.2014.30 |
0.573 |
|
| 2014 |
Toren P, Zoubeidi A. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). International Journal of Oncology. 45: 1793-801. PMID 25120209 DOI: 10.3892/Ijo.2014.2601 |
0.648 |
|
| 2014 |
Bishop JL, Thaper D, Zoubeidi A. The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers. 6: 829-59. PMID 24722453 DOI: 10.3390/Cancers6020829 |
0.674 |
|
| 2014 |
Takeuchi A, Shiota M, Beraldi E, Thaper D, Takahara K, Ibuki N, Pollak M, Cox ME, Naito S, Gleave ME, Zoubeidi A. Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. Molecular and Cellular Endocrinology. 384: 117-25. PMID 24491388 DOI: 10.1016/J.Mce.2014.01.012 |
0.59 |
|
| 2014 |
Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. European Urology. 66: 145-55. PMID 24411988 DOI: 10.1016/J.Eururo.2013.12.019 |
0.608 |
|
| 2014 |
Yamamoto Y, Loriot Y, Beraldi E, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Zoubeidi A, Gleave ME. Biologic consequences of androgen receptor (AR) activity in MDV3100-resistant LNCaP cells and dependence on AR full length. Journal of Clinical Oncology. 32: 74-74. DOI: 10.1200/Jco.2014.32.4_Suppl.74 |
0.502 |
|
| 2014 |
Toren P, Pham S, Kim S, Adomat H, Zoubeidi A, Moore WR, Gleave ME. Anticancer activity of the selective CYP17A1 inhibitor, VT-464, in preclinical models of castrate-resistant prostate cancer. Journal of Clinical Oncology. 32: 104-104. DOI: 10.1200/Jco.2014.32.4_Suppl.104 |
0.601 |
|
| 2014 |
Bishop J, Sio A, Angeles A, Roberts M, Azad A, Chi K, Zoubeidi A. Local and systemic modulation of the PD-L1 pathway is a novel mechanism of Enzalutamide resistance in castration-resistant prostate cancer Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P94 |
0.371 |
|
| 2014 |
Ketola K, Bishop J, Nip KM, Kim S, Ladan F, Gleave M, Zoubeidi A. Abstract 676: Inhibition of FOXM1 targets both high and low PSA expressing prostate cancer cells resistant to Enzalutamide Cancer Research. 74: 676-676. DOI: 10.1158/1538-7445.Am2014-676 |
0.653 |
|
| 2014 |
Xia Y, Beraldi E, Zoubeidi A, Peng L, Gleave M. Abstract 1796: Novel triazole nucleoside inhibits heat shock factor 1 and androgen receptor to fight against prostate cancer Cancer Research. 74: 1796-1796. DOI: 10.1158/1538-7445.Am2014-1796 |
0.694 |
|
| 2014 |
Aguda A, Nguyen N, Caner S, Moore S, Lelj-Garolla B, Zoubeidi A, Gleave M, Brayer G. Studies of Heat shock protein 27 Interactions Acta Crystallographica Section a Foundations and Advances. 70: C804-C804. DOI: 10.1107/S2053273314091955 |
0.305 |
|
| 2014 |
Akamatsu S, Wyatt A, Lin D, Lysakowski S, Zhang F, Kim S, Fazli L, Beltran H, Rubin M, Zoubeidi A, Wang Y, Collins C, Gleave M. MP31-09 IDENTIFICATION OF A RETRO-TRANSPOSON DERIVED GENE ASSOCIATED WITH PROGRESSION TO NEUROENDOCRINE PROSTATE CANCER. Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.918 |
0.637 |
|
| 2014 |
Yamamoto Y, Matsumoto H, Kuruma H, Beraldi E, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Zoubeidi A, Gleave M. MP24-04 CO-TARGETING CLUSTERIN AND THE ANDROGEN RECEPTOR WITH OGX-011 AND AN AR ANTISENSE SYNERGISTICALLY ENHANCES ACTIVITY OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.285 |
0.658 |
|
| 2014 |
Toren P, Pham S, Kim S, Adomat H, Zoubeidi A, Moore W, Gleave M. MP70-05 ANTI-CANCER ACTIVITY OF THE SELECTIVE CYP17A1 INHIBITOR, VT-464, IN PRE-CLINICAL MODELS OF CASTRATE RESISTANT PROSTATE CANCER Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2204 |
0.632 |
|
| 2014 |
Ischia J, Muramaki M, Xia Y, Beraldi E, Miyake H, Zoubeidi A, Cox M, Gleave M. MP52-08 TARGETING IGFBP-2 AND IGFBP-5 IN CASTRATION AND ENZALUTAMIDE RESISTANT PROSTATE CANCER Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1618 |
0.652 |
|
| 2013 |
Beraldi E, Loriot Y, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Zoubeidi A, Gleave ME. Effect of generation 2.5 antisense inhibitor of androgen receptor on MDV3100-resistant prostate cancer cell growth in vitro and in vivo. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 94. PMID 28137156 DOI: 10.1200/Jco.2013.31.6_Suppl.94 |
0.641 |
|
| 2013 |
Toren P, Zoubeidi A. Rational cotargeting of Pim-1 and Akt in prostate cancer. Expert Review of Anticancer Therapy. 13: 937-9. PMID 23984895 DOI: 10.1586/14737140.2013.816461 |
0.564 |
|
| 2013 |
Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Molecular Cancer Therapeutics. 12: 2342-55. PMID 23966621 DOI: 10.1158/1535-7163.Mct-13-0032 |
0.682 |
|
| 2013 |
Rocha J, Zouanat FZ, Zoubeidi A, Hamel L, Benidir T, Scarlata E, Brimo F, Aprikian A, Chevalier S. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. Molecular and Cellular Endocrinology. 381: 140-9. PMID 23906537 DOI: 10.1016/J.Mce.2013.07.017 |
0.778 |
|
| 2013 |
Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A, Gleave M. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. Cancer Research. 73: 5206-17. PMID 23786771 DOI: 10.1158/0008-5472.Can-13-0359 |
0.602 |
|
| 2013 |
Lamoureux F, Zoubeidi A. Dual inhibition of autophagy and the AKT pathway in prostate cancer. Autophagy. 9: 1119-20. PMID 23670050 DOI: 10.4161/Auto.24921 |
0.642 |
|
| 2013 |
Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Molecular Cancer Therapeutics. 12: 567-76. PMID 23493310 DOI: 10.1158/1535-7163.Mct-12-0798 |
0.554 |
|
| 2013 |
Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K, Gleave M, Zoubeidi A. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Research. 73: 3109-19. PMID 23492367 DOI: 10.1158/0008-5472.Can-12-3979 |
0.675 |
|
| 2013 |
Lamoureux F, Thomas C, Crafter C, Kumano M, Zhang F, Davies BR, Gleave ME, Zoubeidi A. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 833-44. PMID 23258740 DOI: 10.1158/1078-0432.Ccr-12-3114 |
0.613 |
|
| 2013 |
Bishop JL, Sangha B, Gleave M, Zoubeidi A. Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P147 |
0.519 |
|
| 2013 |
Gleave M, Zoubeidi A, Chi K. Abstract IA28: Targeting stress-induced molecular chaperones CLU and Hsp27 to inhibit EMT and metastases Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-Ia28 |
0.471 |
|
| 2013 |
Cordonnier T, Bishop JL, Shiota M, Takeuchi A, Nip KM, Gleave M, Zoubeidi A. Abstract C25: Hsp27 is required for EGF-induced epithelial to mesenchymal transition in prostate cancer Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-C25 |
0.602 |
|
| 2013 |
Nakouzi NA, Beraldi E, Shepherd S, Loriot Y, Kim S, Leichmann L, Zoubeidi A, Gleave ME. Abstract 4062: Clusterin downregulation sensitize prostate cancer cells to taxane by modulating mitosis. Cancer Research. 73: 4062-4062. DOI: 10.1158/1538-7445.Am2013-4062 |
0.585 |
|
| 2013 |
Loriot Y, Wyatt A, Nakouzi NA, Beraldi E, Toren P, Nip KM, Gleave M, Zoubeidi A. Abstract 3386: Mechanisms of resistance to enzalutamide in LNCaP models. Cancer Research. 73: 3386-3386. DOI: 10.1158/1538-7445.Am2013-3386 |
0.324 |
|
| 2013 |
Cordonnier TD, Bishop JL, Shiota M, Takeuchi A, Nip KM, Gleave M, Zoubeidi A. Abstract 281: Hsp27 is an essential effector of EGF-induced epithelial to mesenchymal transition in prostate cancer. Cancer Research. 73: 281-281. DOI: 10.1158/1538-7445.Am2013-281 |
0.655 |
|
| 2013 |
Ketola K, Bishop J, Gleave M, Zoubeidi A. Abstract C91: Targeting enzalutamide resistance in prostate cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C91 |
0.691 |
|
| 2013 |
Nakouzi NA, Wang C, Jacoby D, Gleave ME, Zoubeidi A. Abstract C89: Galeterone suppresses castration-resistant and enzalutamide-resistant prostate cancer growth in vitro. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C89 |
0.616 |
|
| 2013 |
Toren P, Kim S, Gleave M, Zoubeidi A. 982 COMBINED TARGETING OF PI3K/AKT AND AR PATHWAY WITH AZD5363 AND ENZALUTAMIDE INDUCES ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF PROSTATE CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.564 |
0.65 |
|
| 2013 |
Yamamoto Y, Beraldi E, Kuruma H, Matsumoto H, Loriot Y, Wyatt A, Mo F, Zhou T, Kim Y, Monia B, MacLeod AR, Fazli L, Zoubeidi A, Gleave M. 321 ANTISENSE INHIBITOR TARGETING FULL LENGTH ANDROGEN RECEPTOR AND ITS SPLICE VARIANTS SUPPRESSES MDV3100 RESISTANT PROSTATE CANCER CELL GROWTH Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1706 |
0.34 |
|
| 2013 |
Thomas C, Lamoureux F, Crafter C, Davies B, Beraldi E, Fazli L, Kim S, Thaper D, Gleave M, Zoubeidi A. 318 Synergistic Targeting Of Pi3K/Akt-Pathway And Androgen-Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1703 |
0.669 |
|
| 2012 |
Loriot Y, Zoubeidi A, Gleave ME. Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor. The Urologic Clinics of North America. 39: 517-31. PMID 23084528 DOI: 10.1016/J.Ucl.2012.07.008 |
0.666 |
|
| 2012 |
Shiota M, Zardan A, Takeuchi A, Kumano M, Beraldi E, Naito S, Zoubeidi A, Gleave ME. Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Research. 72: 5261-72. PMID 22896337 DOI: 10.1158/0008-5472.Can-12-0254 |
0.479 |
|
| 2012 |
Li N, Zoubeidi A, Beraldi E, Gleave ME. GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene. 32: 1933-42. PMID 22689054 DOI: 10.1038/Onc.2012.212 |
0.459 |
|
| 2012 |
Kumano M, Furukawa J, Shiota M, Zardan A, Zhang F, Beraldi E, Wiedmann RM, Fazli L, Zoubeidi A, Gleave ME. Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer Molecular Cancer Therapeutics. 11: 1661-1671. PMID 22675041 DOI: 10.1158/1535-7163.Mct-12-0072 |
0.546 |
|
| 2012 |
Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. The International Journal of Biochemistry & Cell Biology. 44: 1646-56. PMID 22571949 DOI: 10.1016/J.Biocel.2012.04.010 |
0.478 |
|
| 2012 |
Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. The Journal of Pathology. 227: 286-97. PMID 22553170 DOI: 10.1002/Path.4047 |
0.587 |
|
| 2012 |
Crafter C, Davies BR, Thomas C, Lamoureux F, Greenwood H, Garcia-Martinez JM, Mooney L, Cosulich S, Gleave M, Zoubeidi A. Abstract B19: Induction of apoptosis and antitumor activity of the AKT inhibitor AZD5363 is enhanced by combination with hormonal therapies in preclinical models of prostate cancer Cancer Research. 72: B19-B19. DOI: 10.1158/1538-7445.Prca2012-B19 |
0.708 |
|
| 2012 |
Lamoureux F, Thomas C, Kumano M, Zhang F, Gleave M, Zoubeidi A. Abstract A19: Blocking autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363 Cancer Research. 72: A19-A19. DOI: 10.1158/1538-7445.Prca2012-A19 |
0.658 |
|
| 2012 |
Li N, Zoubeidi A, Beraldi E, Gleave ME. Abstract 3261: GRP78 regulates clusterin stability, retrotranslocation, and mitochondrial localization under ER stress in prostate cancer Cancer Research. 72: 3261-3261. DOI: 10.1158/1538-7445.Am2012-3261 |
0.533 |
|
| 2012 |
Zardan A, Cox M, Gleave M, Zoubeidi A. Abstract 1241: In vivo analysis of the role of Lyn tyrosine kinase in castrate-resistant LNCaP xenograft tumor growth Cancer Research. 72: 1241-1241. DOI: 10.1158/1538-7445.Am2012-1241 |
0.644 |
|
| 2012 |
Lamoureux F, Yin M, Zoubeidi A, Gleave M. 245 Downregulation of Hsp27 using OGX-427 induces ER stress and potentiates Hsp90 inhibitors to delay castrate resistant prostate cancer European Urology Supplements. 11: e245. DOI: 10.1016/S1569-9056(12)60242-5 |
0.496 |
|
| 2012 |
Matsumoto H, Kuruma H, Zoubeidi A, Zardan A, Fazli L, Ettinger S, Matsuyama H, Gleave M. 235 Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing AR degradation and repression of FKBP52 in castrate resistant prostate cancer model European Urology Supplements. 11: e235. DOI: 10.1016/S1569-9056(12)60232-2 |
0.656 |
|
| 2012 |
Kuruma H, Matsumoto H, Shiota M, Fanjul A, Briere D, Los G, Lamoureux F, Thomas C, Gleave M, Zoubeidi A. 972 A NOVEL ANTIANDROGEN PF-05234848 SUPPRESSES CASTRATION-RESISTANT AND MDV-3100-RESISTANT PROSTATE CANCER GROWTH
IN VITRO
AND
IN VIVO Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1071 |
0.611 |
|
| 2012 |
Kumano M, Zhang F, Shiota M, Crafter C, Davies B, Zoubeidi A, Gleave M. 962 CLUSTERIN KNOCKDOWN ENHANCES ANTITUMOR ACTIVITY OF A NOVEL AKT INHIBITOR, AZD5363, THROUGH INHIBITION OF AUTOPHAGY IN PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1061 |
0.67 |
|
| 2011 |
Lamoureux F, Yin M, Zoubeidi A, Gleave ME. CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4573. PMID 28023320 DOI: 10.1200/Jco.2011.29.15_Suppl.4573 |
0.632 |
|
| 2011 |
Hayashi N, Peacock JW, Beraldi E, Zoubeidi A, Gleave ME, Ong CJ. Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death and Differentiation. 19: 990-1002. PMID 22179576 DOI: 10.1038/Cdd.2011.184 |
0.414 |
|
| 2011 |
Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, Sorensen PH, Gleave ME. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Molecular Cancer Research : McR. 9: 1755-66. PMID 21987172 DOI: 10.1016/J.Juro.2012.02.550 |
0.627 |
|
| 2011 |
Guo C, Linton A, Kephart S, Ornelas M, Pairish M, Gonzalez J, Greasley S, Nagata A, Burke BJ, Edwards M, Hosea N, Kang P, Hu W, Engebretsen J, Briere D, ... ... Zoubeidi A, et al. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. Journal of Medicinal Chemistry. 54: 7693-704. PMID 21936524 DOI: 10.1021/Jm201059S |
0.562 |
|
| 2011 |
Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A, Gleave ME. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Research. 71: 5838-49. PMID 21737488 DOI: 10.1158/0008-5472.Can-11-0994 |
0.534 |
|
| 2011 |
Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2301-13. PMID 21349995 DOI: 10.1158/1078-0432.Ccr-10-3077 |
0.687 |
|
| 2011 |
Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thüroff JW, Gleave ME. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Molecular Cancer Therapeutics. 10: 347-59. PMID 21216933 DOI: 10.1158/1535-7163.Mct-10-0850 |
0.656 |
|
| 2011 |
Matsumoto H, Kuruma H, Zoubeidi A, Fazli L, Gleave ME. An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model. Journal of Clinical Oncology. 29: 4502-4502. DOI: 10.1200/Jco.2011.29.15_Suppl.4502 |
0.667 |
|
| 2011 |
Lamoureux F, Yin M, Zoubeidi A, Gleave ME. Abstract 623: CLU inhibition using OGX-011 is a new adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer Cancer Research. 71: 623-623. DOI: 10.1158/1538-7445.Am2011-623 |
0.62 |
|
| 2011 |
Zardan A, Cox ME, Gleave ME, Zoubeidi A. Abstract 4545: Lyn tyrosine kinase regulates androgen receptor expression and activity in prostate cancer Cancer Research. 71: 4545-4545. DOI: 10.1158/1538-7445.Am2011-4545 |
0.7 |
|
| 2011 |
Lamoureux F, Thomas C, Crafter C, Davies B, Gleave ME, Zoubeidi A. Abstract 4491: AZD5363, a novel Akt inhibitor, delays prostate cancer progression by inhibiting androgen-receptor activity Cancer Research. 71: 4491-4491. DOI: 10.1158/1538-7445.Am2011-4491 |
0.655 |
|
| 2011 |
Shiota M, Zoubeidi A, Kumano M, Naito S, Nelson CC, Gleave ME. Abstract 3421: Twist1 and clusterin regulate epithelial-mesenchymal transition Cancer Research. 71: 3421-3421. DOI: 10.1158/1538-7445.Am2011-3421 |
0.529 |
|
| 2011 |
Kumano M, Furukawa J, Zoubeidi A, Masaki S, Beraldi E, Gleave M. Abstract 2074: Hsp27 inhibition activates the unfold protein response and autophagy pathway through inhibition of proteasome activity in prostate cancer Cancer Research. 71: 2074-2074. DOI: 10.1158/1538-7445.Am2011-2074 |
0.519 |
|
| 2011 |
Kuruma H, Matsumoto H, Zoubeidi A, Thomas C, Lamoureux F, Gleave M. Abstract 1595: Use of MDV3100 to establish androgen-receptor antagonist resistant LNCaP cells for modelling castrate-resistant progression Cancer Research. 71: 1595-1595. DOI: 10.1158/1538-7445.Am2011-1595 |
0.607 |
|
| 2011 |
Thomas C, Lamoureux F, Crafter C, Davies B, Zoubeidi A, Gleave M. UP-02.098 The Novel AKT-Inhibitor AZD5363 Abrogates Androgen-Receptor Signaling and Delays Hormone-Sensitive and Castration-Resistant Prostate Cancer Progression in vivo Urology. 78: S293. DOI: 10.1016/J.Urology.2011.07.916 |
0.653 |
|
| 2011 |
Lamoureux F, Yin M, Zoubeidi A, Gleave M. 1279 CLU INHIBITION USING OGX-011 IS A NEW ADJUVANT THERAPEUTIC STRATEGY FOR HSP90 INHIBITION IN PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.965 |
0.578 |
|
| 2011 |
Matsumoto H, Kuruma H, Zoubeidi A, Fazli L, Gleave M. 125 CLUSTERIN ANTISENSE INHIBITOR OGX-011 SYNERGIZES ACTIVITY OF SECOND GENERATION ANTI-ANDROGEN, MDV3100, IN CASTRATE RESISTANT PROSTATE CANCER MODEL Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.192 |
0.654 |
|
| 2011 |
Thomas C, Lamoureux F, Crafter C, Davies B, Zoubeidi A, Gleave ME. 728 AZD5363, A NOVEL AKT INHIBITOR, DELAYS PROSTATE CANCER PROGRESSION Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1697 |
0.657 |
|
| 2011 |
Kumano M, Furukawa J, Zoubeidi A, Masaki S, Beraldi E, Gleave M. 615 HSP27 INHIBITION ACTIVATES THE UNFOLD PROTEIN RESPONSE AND AUTOPHAGY PATHWAY THROUGH INHIBITION OF PROTEASOME ACTIVITY IN PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1468 |
0.601 |
|
| 2011 |
Kuruma H, Gust K, Matsumoto H, Zoubeidi A, Thomas C, Lamoureux F, Gleave M. 613 IMMEDIATE, COMPARED TO DEFERRED, COMBINED ANDROGEN BLOCKADE PROLONGS TIME TO CASTRATE-RESISTANT LNCAP PROSTATE CANCER PROGRESSION
IN VIVO Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1466 |
0.672 |
|
| 2010 |
Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, Gleave ME. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Research. 70: 2307-17. PMID 20197463 DOI: 10.1158/0008-5472.Can-09-3252 |
0.566 |
|
| 2010 |
Tavassoli P, Wafa LA, Cheng H, Zoubeidi A, Fazli L, Gleave M, Snoek R, Rennie PS. TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains. Molecular Endocrinology (Baltimore, Md.). 24: 696-708. PMID 20181722 DOI: 10.1210/Me.2009-0229 |
0.611 |
|
| 2010 |
Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1088-93. PMID 20145158 DOI: 10.1158/1078-0432.Ccr-09-2917 |
0.625 |
|
| 2010 |
Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, Nelson CC, Rennie PS, Gleave ME. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Molecular Cancer Research : McR. 8: 119-30. PMID 20068069 DOI: 10.1158/1541-7786.Mcr-09-0277 |
0.63 |
|
| 2010 |
Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. The Prostate. 70: 239-51. PMID 19790237 DOI: 10.1002/Pros.21057 |
0.606 |
|
| 2010 |
Lamoureux F, Yin M, Zoubeidi A, Gleave ME. Abstract 4512: The novel HSP90 inhibitor, PF-04929113, inhibits AR activity and osteoclastogenesis and delays castrate-resistant LNCaP prostate cancer tumor growth Cancer Research. 70: 4512-4512. DOI: 10.1158/1538-7445.Am10-4512 |
0.648 |
|
| 2010 |
Hosseini-Beheshti E, Zoubeidi A, Nip kM, Gleave ME, Guns ES(. Abstract 4150: Exploration of the role of Hsps in exosome derived from prostate cancer cells Cancer Research. 70: 4150-4150. DOI: 10.1158/1538-7445.Am10-4150 |
0.664 |
|
| 2010 |
Hosseini-Beheshti E, Zoubeidi A, Nip KM, Gleave ME, Guns ES. Abstract A39: A newly defined role of clusterin in the formation of exosomes derived from prostate cancer cells Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-A39 |
0.59 |
|
| 2010 |
Lamoureux F, Yin M, Zoubeidi A, Gleave M. 1298 THE NOVEL HSP90 INHIBITOR, PF-04929113, INHIBITS AR ACTIVITY AND OSTEOCLASTOGENESIS AND DELAYS CASTRATE RESISTANT LNCAP PROSTATE CANCER TUMOR GROWTH Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.882 |
0.65 |
|
| 2010 |
Kuruma H, Gust K, Matsumoto H, Zoubeidi A, Fazli L, Loddick S, Brooks N, Gleave M. 1293 A NOVEL ANTI-ANDROGEN ARD1 DOWN-REGULATES ANDROGEN RECEPTOR LEVELS AND ACTIVITY AND SUPPRESSES PROSTATE CANCER LNCAP CELL GROWTH IN VITRO AND IN VIVO Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.877 |
0.656 |
|
| 2010 |
Furukawa J, Zoubeidi A, Beraldi E, Gleave M. 550 HEAT SHOCK PROTEIN 27 INHIBITION ACTIVATES THE UNFOLD PROTEIN RESPONSE PATHWAY THROUGH INHIBITION OF PROTEASOME ACTIVITY IN PROSTATE CANCER Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.770 |
0.548 |
|
| 2010 |
Rocha J, Zouanat F, Zoubeidi A, Hamel L, Aprikian A, Chevalier S. 546 ANDROGEN RECEPTOR ACTIVATION BY THE FER KINASE IN PROSTATE CANCER Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.766 |
0.817 |
|
| 2010 |
Thomas C, Zoubeidi A, Kuruma H, Monia B, Kim Y, MacLeod R, Gleave ME. 234 TARGETING STAT5 DEGRADES ANDROGEN RECEPTOR VIA THE PROTEASOME AND PROLONGS TIME TO TUMOR PROGRESSION POST CASTRATION IN VIVO Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.292 |
0.394 |
|
| 2009 |
Zoubeidi A, Rocha J, Zouanat FZ, Hamel L, Scarlata E, Aprikian AG, Chevalier S. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Molecular Cancer Research : McR. 7: 142-55. PMID 19147545 DOI: 10.1158/1541-7786.Mcr-08-0117 |
0.837 |
|
| 2009 |
Zoubeidi A, Heroux D, Nip KM, Majd M, Beraldi E, Gleave ME. TARGETING HSP27 ABROGATES IL-6 SIGNALLING PATHWAY AND PROLONGS TIME FOR CASTRATED RESISTANT PROSTATE CANCER Journal of Urology. 181: 514-514. DOI: 10.1016/S0022-5347(09)61451-8 |
0.59 |
|
| 2009 |
Hayashi N, Beraldi E, Peacock J, Zoubeidi A, Kuruma T, Egawa S, Ong C, Gleave ME. HSP27 BLOCKADE SELECTIVELY INHIBITS GROWTH OF PTEN DEFICIENT TUMORS BY REGULATING PEA-15 ACTIVITY IN AN AKT DEPENDENT MANNER Journal of Urology. 181: 513-514. DOI: 10.1016/S0022-5347(09)61450-6 |
0.352 |
|
| 2009 |
Zoubeidi A, Zardan A, Lock J, Beraldi E, Fazli L, Gleave ME. HSP27 PROMOTES IGF-1 SURVIVAL SIGNALING IN PROSTATE CANCER VIA P90RSK-DEPENDENT PHOSPHORYLATION AND INACTIVATION OF BAD Journal of Urology. 181: 513-513. DOI: 10.1016/S0022-5347(09)61449-X |
0.609 |
|
| 2009 |
Jerde TJ, Zoubeidi A, Gleave ME, Bushman W. INDUCTION OF HEAT SHOCK PROTEIN 25 ACTIVITY DURING INFLAMMATORY REACTIVE HYPERPLASIA OF THE PROSTATE Journal of Urology. 181: 188-189. DOI: 10.1016/S0022-5347(09)60543-7 |
0.503 |
|
| 2008 |
Chi KN, Zoubeidi A, Gleave ME. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opinion On Investigational Drugs. 17: 1955-62. PMID 19012510 DOI: 10.1517/13543780802528609 |
0.541 |
|
| 2008 |
Hadaschik BA, Jackson J, Fazli L, Zoubeidi A, Burt HM, Gleave ME, So AI. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. Bju International. 102: 610-6. PMID 18384625 DOI: 10.1111/J.1464-410X.2008.07669.X |
0.383 |
|
| 2008 |
Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. Bju International. 102: 389-97. PMID 18336596 DOI: 10.1111/J.1464-410X.2008.07618.X |
0.627 |
|
| 2008 |
Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. International Journal of Cancer. Journal International Du Cancer. 122: 2368-76. PMID 18240145 DOI: 10.1002/Ijc.23406 |
0.676 |
|
| 2008 |
Zoubeidi A, Beraldi E, Nguyen YT, Gleave ME. TARGETING THE CYTOPROTECTIVE CHAPERONE CLUSTERIN AS A STRATEGY TO INCREASE THE ANTICANCER ACTIVITY OF THE HSP90 INHIBITOR 17-ALLYLAMINO-DEMETHOXY GELDANAMYCIN Journal of Urology. 179: 225-225. DOI: 10.1016/S0022-5347(08)60648-5 |
0.318 |
|
| 2007 |
Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research. 67: 10455-65. PMID 17974989 DOI: 10.1158/0008-5472.Can-07-2057 |
0.631 |
|
| 2007 |
Hayashi N, Beraldi E, Peacock J, Zoubeidi A, Ong C, Gleave ME. 1126: HSP27 Controls Cell Growth and Apoptosis in LNCAP Cells by Regulating the Anti-Apoptotic Phosphoprotein, PEA-15 Journal of Urology. 177: 372-372. DOI: 10.1016/S0022-5347(18)31340-5 |
0.339 |
|
| 2007 |
Zoubeidi A, Beraldi E, Zardan A, Gleave ME. 146: Clusterin is a Ubiquitin Binding Protein Involved in Murr1 and 1-KB Proteasomal Degradation to Confer Cell Survival in Prostate Cancer Journal of Urology. 177: 50-50. DOI: 10.1016/S0022-5347(18)30411-7 |
0.595 |
|
| 2006 |
Zoubeidi A, Sinnemann S, Gleave ME. 812: Androgen and HSP27 Cooperatively Interact to Facilitate Genomic and Non-Genomic Activity of the Androgen Receptor to Enhance Prostate Cancer Survival Journal of Urology. 175: 262-262. DOI: 10.1016/S0022-5347(18)33048-9 |
0.551 |
|
| 2000 |
Allard P, Zoubeidi A, Nguyen LT, Tessier S, Tanguay S, Chevrette M, Aprikian A, Chevalier S. Links between Fer tyrosine kinase expression levels and prostate cell proliferation. Molecular and Cellular Endocrinology. 159: 63-77. PMID 10687853 DOI: 10.1016/S0303-7207(99)00205-1 |
0.822 |
|
| Show low-probability matches. |